Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

36.98 +0.50 (+1.37%)

Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Via Finterra

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Via The Motley Fool

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗

February 25, 2026

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Via The Motley Fool

Topics Stocks

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Via The Motley Fool

1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗

February 25, 2026

Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.

Via The Motley Fool

Topics Economy

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

February 25, 2026

From Schall Law

Via GlobeNewswire

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Via Stocktwits

Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 ↗

February 25, 2026

Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.

Via Benzinga

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗

February 25, 2026

It would be a near-miracle gain.

Via The Motley Fool

Why Eli Lilly Stock Slumped Today ↗

February 24, 2026

Investors worried that the company could take quite a revenue hit due to a competitor's move.

Via The Motley Fool

Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA ↗

February 24, 2026

Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.

Via Stocktwits

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report ↗

February 24, 2026

According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.

Via Stocktwits

Topics Artificial Intelligence

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗

February 24, 2026

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Via Stocktwits

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗

February 23, 2026

Is this the best way to cash in on the weight-loss gold rush?

Via The Motley Fool

Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗

February 23, 2026

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

Via The Motley Fool

Topics Stocks

Stock Market Today, Feb. 23: Nvidia Earnings Loom as Tariff Concerns Drive Dow 800 Points Lower ↗

February 23, 2026

AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026.

Via The Motley Fool

Topics Artificial Intelligence Government Stocks

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

Via MarketMinute

Check out the stocks that are attracting the most attention and driving market activity. ↗

February 23, 2026

Via Chartmill

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

February 23, 2026

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Via The Motley Fool

Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO

February 23, 2026

From The DJS Law Group

Via Business Wire

Why Eli Lilly Stock Just Popped ↗

February 23, 2026

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).

Via The Motley Fool

Why Novo Nordisk Stock Just Crashed ↗

February 23, 2026

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.

Via The Motley Fool

High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026

February 23, 2026

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

February 23, 2026

From The Schall Law Firm

Via Business Wire

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Via MarketMinute

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

Via MarketMinute

Topics Earnings

These stocks are moving in today's pre-market session ↗

February 23, 2026

Via Chartmill

1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock ↗

February 23, 2026

Novo Nordisk investors get a second bite at the Ozempic apple.

Via The Motley Fool

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

February 23, 2026

Viking stock has plenty of room to run.

Via The Motley Fool

Why Is NVO Stock Falling Pre-Market Today? ↗

February 23, 2026

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

Via Stocktwits

Topics Government

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today